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Abstract 
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most aggressively malignant tumors with 
dismal prognosis. Profilin 2 (PFN2) is an actin‑binding protein that regulates the dynamics of actin polymerization and 
plays a key role in cell motility. Recently, PFN2 have emerged as significant regulators of cancer processes. However, 
the clinical significance and biological function of PFN2 in ESCC remain unclear.
Methods: PFN2 protein expression was validated by immunohistochemistry (IHC) on tissue microarray from Chinese 
Han and Kazakh populations with ESCC. The associations among PFN2 expression, clinicopathological features, and 
prognosis of ESCC were analyzed. The effects on cell proliferation, invasion and migration were examined using MTT 
and Transwell assays. Markers of epithelial–mesenchymal transition (EMT) were detected by Western blot analysis.
Results: Compared with normal esophageal epithelium (NEE), PFN2 protein expression was markedly increased in 
low‑grade intraepithelial neoplasia (LGIN), high‑grade intraepithelial neoplasia (HGIN), and ESCC, increased gradually 
from LGIN to ESCC, and finally reached high grade in HGIN in the Han population. Similarly, PFN2 protein was more 
overexpressed in ESCC than in NEE in the Kazakh population. The results of Western blot analysis also showed that PFN2 
expression was significantly higher in the ESCC tissue than in a matched adjacent non‑cancerous tissue. PFN2 expression 
was positively correlated with invasion depth and lymph node metastasis. High PFN2 expression was significantly cor‑
related with short overall survival (OS) (P = 0.023). Cox regression analysis revealed that PFN2 expression was an inde‑
pendent prognostic factor for poor OS in ESCC. Downregulation of PFN2 inhibited, rather than proliferated, cell invasion 
and migration, as well as induced an EMT phenotype, including increased expression of epithelial marker E‑cadherin, 
decreased mesenchymal marker Vimentin, Snail, Slug and ZEB1, and morphological changes in ESCC cells in vitro.
Conclusions: Our findings demonstrate that PFN2 has a novel role in promoting ESCC progression and metastasis 
and portending a poor prognosis, indicating that PFN2 could act as an early biomarker of high‑risk population. Target‑
ing PFN2 may offer a promising therapeutic strategy for ESCC treatment.
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Background
Esophageal squamous cell carcinoma (ESCC), a preva-
lent malignant neoplasm, is the sixth leading cause of 
cancer-related deaths globally [1, 2]. China has the high-
est incidence and mortality rate for ESCC, the dominant 
pathological type of esophageal carcinoma (accounting 
for 90 %) [3, 4]. Despite the improvement in diagnosis and 
treatment, the survival of patients with advanced stages 
of ESCC remains bleak because of early lymph node 
metastasis, with a 10  % 5  year survival rate for patients 
[5–7]. In sharp contrast, the 5 year survival rate of patient 
with early stage of ESCC is higher than 90 % [8]. How-
ever, most patients with ESCC are diagnosed at the 
advanced stage at the time of initial diagnosis. Although 
various biomarkers have been identified over the past few 
decades, sensitive and specific molecule markers for early 
detection and exact indicators for ESCC prognosis are 
not currently available [9, 10]. Therefore, novel biomark-
ers that can help in early detection, precise prognosis and 
individualized therapy of ESCC patients are needed.
Profilins are 12–15  kDa actin-binding proteins found 
in eukaryotes [11]. These proteins sequester actin mono-
mer protein and regulate the dynamics of actin polym-
erization [12, 13]. In mammals, four discrete profilin 
genes (PFN1, PFN2, PFN3, and PFN4) have been identi-
fied. PFN1, the mainstay of the profilin family, is ubiqui-
tously expressed in all cell types, except skeletal muscle 
[13, 14]. In amniotes, two alternatively spliced variants of 
PFN2 (PFN2a and PFN2b) have been identified. PFN2a is 
a major isoform that is predominantly expressed in neu-
ronal cells. Isoform PFN2b, of which mRNA is detectable 
in a finite number of adult tissues mainly in the kidney, 
is rare [15, 16]. PFN3 and PFN4 expressions are limited 
to the testis [17, 18]. In general, PFN1 and PFN2, as the 
most common profilins in mammalian cells, display 
similar actin monomer-binding properties [19]. Profi-
lin accelerates the extension of the uncapped actin fila-
ment in the presence of formin and then depolymerizes 
the capped actin filament, thereby leading to cytoskel-
etal changes [20, 21]. In addition, the disruption of pro-
filin by gene deletion of PFN1 in null mice [22] or by 
anti-profilin transfection in bovine oocytes [23], results 
in early embryonic death. In response to depolarization, 
those mice lacking PFN2 exhibited a hindered synaptic 
actin polymerization [24]. These phenomena indicate 
the non-redundant roles of PFN1 and PFN2 in vertebrate 
gastrulation.
In recent years, the properties of the profilin fam-
ily that is involved tumors in progression have been 
reported. PFN1 has been viewed as a negative regulator 
for the migration and invasion of breast cancer cells [25–
27]. However, a recent report highlighted the opposite 
roles of PFN1 and PFN2 in the membrane protrusion, 
cell migration and invasion of breast cancer cells [28]. 
Another recent report showed that PFN1 had contrast-
ing effects on breast cancer in a context-dependent man-
ner [29]. Other reports suggested that post-translational 
modifications, such as phosphorylation of PFN1 at Ser 
137 or Tyr 129, could change the properties of cancer 
cells [30–32]. Hence, the roles of profilin in various can-
cers need to be further clarified. Similarly, the biologi-
cal function of PFN2 in digestive tract tumors remains 
controversial. In oral squamous cell carcinoma (OSCC), 
PFN2 inhibits tumor growth and aggressiveness [33]. 
Nevertheless, PFN2 significantly enhanced migration and 
invasion ability of HT29 human colorectal cancer stem 
cells [34]. However, only few studies have investigated the 
role of PFN2 in ESCC progression.
In this study, we explored the expression of PFN2 in 
ESCC and precursor lesions from two different races 
and then analyzed the associations of PFN2 expression 
with the clinicopathologic features of ESCC. Functional 
studies were performed to identify the undiscovered bio-
logical function of PFN2 in ESCC cells. In sum, PFN2 
assumes a tumor-promoting role in ESCC progression 
and metastasis by inducing EMT. PFN2 may also func-
tion as an independent prognostic biomarker and chem-
otherapeutic target for ESCC patients from Han and 
Kazakh ethnic populations, particularly those who are 
suffering from early stages of cancer.
Methods
Patients and tissue specimens
The ESCC tissues used for IHC staining of PFN2 were 
gathered from two separate groups of ESCC. One group 
comprised 192 Han Chinese patients with ESCC col-
lected between 1997 and 2013 from the First University 
Hospital, Shihezi University School of Medicine. The 
other group included 168 Kazakh ESCC patients whose 
data were gathered between 1984 and 2011 from Xinji-
ang Yili Prefecture Friendship Hospital, People’s Hos-
pital of Xinjiang Uyghur Autonomous Region, and the 
First University Hospital, Shihezi University School of 
Medicine. No restrictions regarding sex, age, or stage 
of disease were placed. Except for diagnostic biopsies, 
iatrochemistry, or radiotherapy, none of the patients 
received prior surgery. Data on clinicopathologic param-
eters, such as invasion depth and lymph node metas-
tasis, were collected. Tumor node metastasis (TNM) 
stages were assessed for each case in accordance with 
the seventh edition of the AJCC cancer-staging manual 
[35]. All patients involved in the study gave their written 
informed consent, and the research protocol used in this 
study was approved by the medical ethics and human 
clinical trial committee of the Shihezi University School 
of Medicine.
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The clinical characteristics of patients from both vali-
dation centers are listed in Table  1. Immediately after 
surgery, 192 cancerous tissues, together with their 135 
adjacent mucosa, were collected from the Han patient 
group. A total of 168 cancerous tissues, with their 55 
adjacent mucosa, were collected from the Kazakh patient 
group. The tissues were fixed in 10  % formalin for 24  h 
and then embedded in paraffin. Moreover, from the Han 
group samples, 85 precursor lesions, called esophageal 
squamous intraepithelial neoplasia (ESIN), were selected, 
including 52 LGIN and 33 HGIN. The diagnoses of all 
the subjects were from two pathologists independently. 
Clinical and pathological information of all cases were 
acquired from medical records. Follow-ups were con-
ducted on 71 Han patients by phone or other methods, 
with a follow-up deadline of 10 July 2015.
Tissue microarray fabrication and immunohistochemistry 
analysis
Tissue microarray (TMA) construction and IHC pro-
cess were implemented according to previous research 
[36]. In brief, paraffin-embedded samples was first cut 
into 4-μm-thick slices and stained using hematoxylin and 
eosin (HE). Many cancerous regions of each sample were 
distinguished from HE-stained slides. Subsequently, the 
aforementioned areas were located to the ready paraffin 
block for TMA fabrication. Then, we bore a hole in these 
regions and inserted into a recipient paraffin block using 
a tissue arrayer with a hollow needle with a diameter of 
1.0 mm (ALPHELYS, Plaisir, France). Finally, serial slices 
were built from the TMA blocks for IHC staining.
PFN2 protein expression was detected using the Envi-
sion system (Dako, Carpinteria, CA). Next, the tissue 
slices were prepared on microslides and baked at 65  °C 
for 2  h and deparaffinized using xylene and rehydrated 
using alcohol. Then, the slices were immersed in hydro-
gen peroxide (3  %) for 10  min to eliminate endogenous 
peroxidase. Subsequently, antigen retrieval was imple-
mented by heating the tissue slices in a pressure cooker 
under high power for 10 min in a citrate buffer solution. 
The tissue sections were then incubated with anti-PFN2 
antibody (ab55611; Abcam, Cambridge, MA; dilution 1: 
400) at 4 °C overnight. By contrast, negative control sec-
tions were incubated with PBS. The next day, the slides 
were incubated with a second antibody for 30  min at 
37  °C. Afterward, these slices were covered with a fresh 
diaminobenzidine solution then stained with hema-
toxylin and dehydrated with graded alcohol and xylene. 
Finally, neutral balsam (ZSGB-Bio, Beijing, China) and 
coverslips were added, and the slices were air dried 
before the analysis.
Semi‑quantitative assessment and scoring
With respect to the assessment of IHC results, we 
referred to a previous scoring method [37]. The expres-
sion of PFN2 was semi-quantitatively scored on the 
basis of the percentage of positive cells and cytoplasmic/
nuclear staining intensity. The percentage of positive cells 
were 0 (<5  % positive cells), 1 (6–25  % positive cells), 2 
(26–50 % positive cells), 3 (51–75 % positive cells), or 4 
(>75  % positive cells). The cytoplasmic/nuclear stain-
ing intensity was classified into the following: 0 score 
(negative), 1 (light yellow), 2 (yellow), and 3 (brown). The 
percentage of positive cells and staining intensity were 
then multiplied to obtain the IHC score (IS) for each 
patient. All immunostained results were assessed by two 
pathologists independently and finally assigned a con-
sistent score. If the two pathologists disagreed over the 
immunohistochemical results, a third pathologist was 
invited to assist in analyzing the results. Thus, the IS 
ranged from 0 to 12 scores. The optimal cut-off values for 
the evaluation system can be perceived as follows: high 
expression of PFN2 was defined as an expression index 
Table 1 PFN2 clinicopathological characteristics of patients 
with ESCC from Chinese Han and Kazakh population
a Histologic grade was based on WHO classification published in 2010
b TNM stage was assessed according to the 7th edition of the AJCC Cancer 
Staging Manual
Characteristic Han ethnic Kazakh ethnic
(N = 192) (N = 168)
No % No %
Age at surgery, years
 Median 62.5 57.4
 Range 42–81 34–75
Gender
 Male 137 71.4 108 64.3
 Female 55 28.6 60 35.7
Differentiationa
 Well 67 34.9 39 23.2
 Moderate + Poor 125 65.1 129 76.8
Invasion depth
 T1–T2 79 41.1 83 49.4
 T3–T4 113 58.9 85 50.6
Lymph node metastasis
 No 127 66.1 79 47.0
 Yes 65 33.9 89 53.0
TNM stageb
 I + II 154 80.2 111 66.1
 III + IV 38 19.8 57 33.9
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score of ≥4, and low expression of PFN2 was defined as 
an expression index score of <4. These cases were divided 
into two groups based on their IS of PFN2 staining. Cases 
with scores of ≥4 were categorized as the high expression 
group, and cases with a score of <4 were categorized as 
the low expression group.
Cell culture and cell transfection
Three EC cell lines (EC9706, Eca109, TE-1) were obtained 
from the Institute of Biochemistry and Cell Biology of 
the Chinese Academy of Sciences. Cell culture was per-
formed in DMEM Medium (GIBCO-BRL) in addition 
with 10 % fetal calf serum, 100 mg/mL streptomycin, and 
100 U/mL penicillin in moist air containing 5 % CO2 at 
37  °C. Oligonucleotide small interfering RNA (siRNA) 
duplexes were synthesized by GenePharma (Shanghai, 
China). The following siRNA sequence for PFN2 was 
used: 5′-CAU AUG AAC UCG CUU UAU A-3′. A non-
target scrambled siRNA was used as the negative control: 
5′-UUC UCC GAA CGU GUC ACG UTT-A-3′. The cells 
were transfected with 130 nM siRNA targeting PFN2 or 
RNAi negative control duplexes using HiPerFect trans-
fection reagents (Qiagen, Hilden, Germany) in serum-
free conditions according to the Quick-Start Protocol.
Western blot analysis
Western blot analyses were performed on cell lysate pre-
pared from three esophageal cancer cell lines and esoph-
ageal tissue as described previously. Equal amount of 
protein lysate were loaded and separated on 10 % SDS–
polyacrylamide gel electrophoresis and then transferred 
to a PVDF membrane (Millipore, USA). After being 
blocked by 5  % fat-free milk in TBS buffer, membranes 
were probed with the following antibodies overnight at 
4 °C: mouse monoclonal anti-PFN2 (Abcam; 1:1000 dilu-
tion), rabbit anti-E-cadherin (Santa Cruz; 1:200 dilution), 
rabbit anti-Vimentin (Abcam; 1:1000 dilution), rabbit 
anti-Snail (Proteintech; 1:500 dilution), rabbit anti-Slug 
(Proteintech; 1:200 dilution), rabbit anti-ZEB1 (Protein-
tech; 1:500 dilution) and mouse anti-β-actin (Zhongshan 
Biotechnology; 1:1000). Bound antibodies were detected 
with secondary HRP-conjugated antibodies (Santa Cruz) 
for 2 h at room temperature. After washing, the resulting 
bands were visualized using the standard ECL procedure 
(Kangwei, Beijing). Images were acquired using the image 
acquisition system (BioRad, USA) and their grayscale 
value was analyzed by the image analysis program (Gel-
Pro Analyzer 4.0, USA).
Measurement of cell proliferation
Cells (4 × 103 cells/well) were seeded at 96-well plates in 
triplicate. The cells were incubated for 24, 48, and 72 h, and 
were then stained with 20 μL 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) dye (5  mg/
mL, Solarbio) for 4  h. Subsequently, supernatants were 
removed, and 150 μL of DMSO was added to each well. 
The plates were shook rapidly until the formazan crystals 
dissolved completely. The absorbance value of each well 
was detected at 490 nm using a spectrophotometer (Bio-
Rad, USA). Independent experiments were repeated three 
times.
Cell migration and invasion assays
Cell migration and invasion assays were performed as 
previously described [37]. Migration assay was per-
formed by using Transwell insert chambers (Corning, 
USA). Transfected cells measuring 8 ×  104 were plated 
onto the top surface of the chamber in triplicate. After 
incubation for 24  h under suitable conditions, non-
invaded cells were removed, and the membranes contain-
ing the invaded cells were fixed and stained with 0.1  % 
crystal violet. More than six fields were counted for each 
sample. Three independent experiments were performed. 
For the cell invasion assay, the process was analogous to 
the cell migration assay, except for that the membranes 
were smeared with Matrigel (BD Biosciences, USA) and 
the seeded cells were incubated for 8 h.
Statistical analysis
Statistical analysis of the experimental data was per-
formed using SPSS 19.0 software (IBM Corporation, 
Armonk, NY, USA). Categorical data were compared 
using χ2 test and Fisher’s exact test to analyze the dif-
ferences in PFN2 expression and clinical characteristics. 
The sensitivity and specificity of ESCC and precancerosis 
forecast were assessed by receiver operating character-
istic (ROC) curves. Survival curves were analyzed using 
the Kaplan–Meier method. A Cox regression model was 
used to analyze the independent prognostic factors. All 
statistical results were demonstrated using GraphPad 
Prism 5 software. For all tests, the P values of less than 
0.05 were considered statistically significant.
Results
PFN2 is overexpressed in ESIN and ESCC tissue compared 
with NEE tissue
To determine the clinical relevance of PFN2 and explore 
its potential role in ESCC progression, we detected the 
expression of PFN2 protein by IHC staining in NEE, 
LGIN, HGIN, and ESCC tissues gathered from the Chi-
nese Han and Kazakh populations. The IHC results 
revealed that PFN2 staining was mainly located in the 
nuclei/cytoplasm, and the distribution of PFN2 staining 
was significantly different during the different develop-
ment phases of ESCC. For the Han population, the IHC 
analysis displayed that the frequency of PFN2 protein 
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overexpression was lowest in the NEE tissue (8.1 %), but 
its frequency increased gradually along with the progress 
of esophageal cancer, with 40.4  % (21/52) of LGIN and 
91.0  % (30/33) of HGIN. Meanwhile, a slight decrease 
in frequency was observed at 82.8 % (159/192) of ESCC, 
but a high expression level of PFN2 protein was still 
observed. In NEE, PFN2 staining was weak or negative 
and was predominantly observed in the nuclei/cytoplasm 
of basal cells (Fig.  1a); however, PFN2 was expressed in 
HGIN and ESCC cells with the strongest signal in nuclei/
cytoplasm (Fig. 1b, c). The tendency of PFN2 overexpres-
sion rates exhibited a progressive increase in NEE, LGIN, 
and ESCC, and peaked in HGIN (Fig. 1d). Moreover, the 
four-level score (0–1, 2–3, 4–8, and 9–12) distribution 
of PFN2 protein expression in the different development 
stage of ESCC was significantly distinct (Fig. 1e). An in-
depth analysis uncovered that the overexpression rates 
of PFN2 protein increased significantly in LGIN, HGIN, 
and ESCC compared with that in NEE (P < 0.001). Mean-
while, significant differences were observed between 
LGIN and HGIN (P  <  0.001), as well as between LGIN 
and ESCC (P < 0.001). PFN2 overexpression was highest 
in HGIN, not ESCC. However, the difference between 
these two subgroups was not statistically significant 
(P > 0.05, Table 2). The expression of PFN2 protein was 
also analyzed in the Kazakh patients. The statistical anal-
ysis showed that the staining density of PFN2 in ESCC 
tissue was distinctly stronger than that in adjacent nor-
mal tissue in the Kazakh population (P < 0.001, Fig. 2a, 
b, c). High PFN2 expression was detected in 146/168 
(86.9 %) of ESCC tissues and only in 8/55 (14.5 %) of nor-
mal samples. The results were constant the findings from 
the Han patients, which indicated no differences with 
regard to the profile of PFN2 expression between differ-
ent histologic types gathered from the Chinese Han and 
Kazakh groups (Table 3).
Furthermore, we examined the expression of PFN2 in 
11 matched pairs of ESCC and adjacent normal tissue by 
Western blot. As shown in Fig. 2d, e, in all cases, PFN2 
expression in the ESCC tissue was visibly higher than 
in adjacent normal tissue from the same ESCC patient 
(P < 0.01), which was consistent with the findings in IHC 
with respect to the PFN2 expression.
PFN2 expression is associated with lymph node metastasis 
and invasion depth in ESCC
To ascertain whether the protein expression levels of 
PFN2 were indicative of the development state of ESCC, 
we further investigated the relationship between PFN2 
expression and clinicopathological characteristics in two 
independent groups of patients with ESCC. As summa-
rized in Table  4, in Han patients, a high PFN2 expres-
sion more frequently occurred in ESCC tissue with deep 
invasion (P = 0.004), and a positive lymph node metas-
tasis occurred in Kazakh patients (P = 0.010). However, 
no significant correlation between PFN2 expression and 
other clinicopathological variables, such as gender, age, 
differentiation, and TNM stage, were found among the 
Chinese Han and Kazakh groups.
Upregulated PFN2 expression predicts unfavorable 
prognosis in ESCC patients
To assess the value of PFN2 for the prognosis of post-
surgical ESCC patients, the relationship between PFN2 
expression and OS of ESCC was analyzed using Kaplan–
Meier method. The median survival time for patients 
with high PFN2 expression was 12  months (range, 
1–96 months) and 42 months (range, 1–96 months) for 
patients with low PFN2 expression, which indicated 
that ESCC patients with high PFN2 expression had sig-
nificantly shorter OS rates and greater risk of death 
than those with low PFN2 expression (log-rank test, 
χ2 = 5.203, P = 0.023) (Fig. 3a, b).
In addition, Cox proportional hazards modes were 
utilized to identify independent prognostic factors for 
ESCC survival. A univariate Cox analysis revealed that 
PFN2 protein level (HR = 2.669, 95 % CI = 1.147–6.209, 
P  =  0.023), together with invasion depth (HR  =  3.085, 
95  % CI  =  1.079–8.819, P  =  0.036) and TNM stage 
(HR  =  2.981, 95  % CI  =  1.380–6.437, P  =  0.005), was 
responsible for OS of ESCC patients (Table 5). Further-
more, in a multivariate analysis of significant factors, 
only PFN2 protein level (HR = 2.465, 95 % CI = 1.020–
5.955, P  =  0.045) and TNM stage (HR  =  3.037, 95  % 
CI = 1.094–8.833, P = 0.033) were independently asso-
ciated with OS of ESCC (Table  5). Overall, the data 
indicated that the PFN2 overexpression independently 
predicted a worse prognosis for ESCC patients.
PFN2 may be a feasible diagnostic bioindicator for ESCC 
and ESIN
Using the adjacent normal mucosa as control, the ROC 
curves for distinct types of tissue elucidated the point on 
the curve closest to (0.0, 1.0), which maximizes both sen-
sitivity and specificity for ESCC, HGIN, and LGIN. Using 
the IHC cut-off scores of PFN2 as a proposed standard, 
the ESCC, HGIN, and LGIN tissue were distinguished 
easily from the control. In the Chinese Han populations, 
in terms of cut-off score of 4, the sensitivity and speci-
ficity values for ESCC were 96.6 and 63.0 %. HGIN and 
LGIN were analyzed to obtain sensitivity and specific-
ity values of 97.0 and 63.0 %, as well as 67.3 and 63.0 %, 
respectively. In the Kazakh group, the sensitivity and 
specificity values for ESCC were 90.1 and 57.3 %, respec-
tively (cut-off score of 4) (Fig. 4, Additional file 1: Table 
S1). These findings support the conjecture that PFN2 
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may be a feasible diagnostic bioindicator for ESCC and 
ESIN.
PFN2 induces EMT phenotype and promotes the migration 
and invasion of ESCC cell lines
EMT contributes to tumor invasion and metastasis in 
various cancers; therefore, we evaluated whether essen-
tial EMT-related markers were altered in our model. 
From the results of Western blot, we observed an effi-
cient knockdown of PFN2, with over 50  % decrease in 
protein level in the PFN2-siRNA transfected ESCC cells, 
and the upregulated epithelial marker E-cadherin and 
significantly decreased mesenchymal markers: Vimen-
tin, Snail, Slug and ZEB1 in Eca109, EC9706, and TE-1 
cells with knockdown of PFN2 compared with the con-
trol groups (Fig. 5a, b, c, d). The Western blot results sug-
gested that PFN2 could regulate the molecular changes of 
EMT in ESCC cells.
Our data on clinical samples showed that PFN2 expres-
sion is positively associated with invasion depth and 
lymph node metastasis of ESCC patients. Hence, we 
wanted to determine whether PFN2 is essential for ESCC 
cell migration and invasion in  vitro. After silencing of 
PFN2, Eca109 cells exhibited a morphological change 
from an elongated fibroblastic phenotype to an epithelial 
cobblestone phenotype, which indicated that EMT weak-
ens (Fig. 5e). Subsequently, Transwell assays showed that 
depletion of PFN2 significantly suppressed the migra-
tion and invasion of Eca109 and EC9706 cell lines. As 
shown in Fig. 6a, b, the number of cells that traversed the 
membrane was significantly decreased in PFN2-siRNA-
treated groups compared with that in the control groups 
(P < 0.01). Similarly, the number of cells that invaded the 
Matrigel membrane was also significantly decreased in 
PFN2-siRNA-treated groups compared with that in the 
control groups (P < 0.01) (Fig. 6c, d). These results were 
consistent with the statistical results of clinical speci-
mens, indicating that PFN2 is essential for the migrant 
and invasive properties of ESCC cells. Taken together, 
PFN2 may promote the migration and invasion of ESCC 
cell lines by inducing EMT phenotype.
Discussion
Accumulating evidence suggests that PFN2 may be 
linked with multiple cancers. However, the roles of PFN2 
in the reported tumors were inconsistent. In OSCC, 
PFN2 serves as a negative regulator of tumor growth and 
aggressiveness [33], whereas PFN2 significantly increases 
migration and invasion ability of lung cancer and colo-
rectal cancer stem cells [19, 34]. However, whether PFN2 
serves a similar role in the progression of ESCC is cur-
rently unknown. For the first time, we found that the 
PFN2 expression in the ESCC tissues from Chinese and 
Kazakh ESCC patients both increased similar to that in 
their ESIN tissues. Moreover, in vitro assays revealed the 
biological role of PFN2 in facilitating the migration and 
invasion of cancer cells by regulating the EMT phenotype 
of ESCC, thereby proving that PFN2 might be a potential 
biomarker for the diagnosis and a therapeutic target for 
the treatment of ESCC.
As a highly aggressive tumor, ESCC involves a multi-
stage process, in which NEE follows a series of histologi-
cal and genetic progression, goes through noninvasive 
precursor lesions, and finally becomes an invasive can-
cer [38]. Many reports indicate that precursor lesions 
have prognostic significance for ESCC because dysplastic 
lesions are frequently encountered in ESCC tissues [39]. 
Therefore, the expression of proteins in precursor lesions 
is usually predictive of ESCC progression. We found that 
the overexpression of PFN2 was positively related with 
(See figure on previous page.) 
Fig. 1 IHC analysis of PFN2 protein in adjacent normal tissues, precancerous lesions, and ESCC tissues from Chinese Han population. Typical PFN2 
immunostaining in a NEE, b LGIN and HGIN, and c ESCC in the Chinese Han population (top image magnification ×40; middle and bottom image 
magnification ×200; bottom image stands for negative control) PFN2 staining was located to the nuclei/cytoplasm. d (Box plot) Range of PFN2 
immunoreactivity score in NEE, LGIN, HGIN, and ESCC tissues (**P < 0.01, ***P < 0.001). e (Bar chart) Distribution ratio of NEE, LGIN, HGIN and ESCC 
tissues in four‑level score (0–1, 2–3, 4–8, and 9–12) of PFN2 expression
Table 2 PFN2 protein expression during cancer progression by IHC analysis in Han population
* P < 0.05, as determined by Pearson’s χ2 test
Cancer progression Immunostaining P value
Low (%) High (%)
Normal esophageal epithelium① 124 (91.9) 11 (8.1) ①:② P < 0.001*; ①:③ P < 0.001*
Low grade intraepithelial neoplasia② 31 (59.6) 21 (40.4) ②:③ P < 0.001*; ②:④ P < 0.001*
High grade intraepithelial neoplasia③ 3 (9.0) 30 (91.0) ③:④ P = 0.241
ESCC④ 33 (17.2) 159 (82.8) ①:④ P < 0.001*
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Fig. 2 IHC analysis of PFN2 protein in adjacent normal tissues and ESCC tissues from Kazakh population. Typical PFN2 immunostaining in a NEE 
and b ESCC in the Chinese Kazakh population (top image magnification ×40; middle and bottom image magnification ×200; bottom image stands 
for negative control). PFN2 staining was localized to the nuclei/cytoplasm. c (Box plot) Range of PFN2 expression score in NEE and ESCC tissues 
(***P < 0.001). d PFN2 expression at the protein level was detected by Western blot analysis in 11 matched pairs of ESCC tissues (T) and adjacent 
normal tissues (N). β‑actin was used as an endogenous control. e Bar chart showing the relative PFN2 protein expression level to β‑actin in ESCC 
tissues and paired NEE tissues (**P < 0.01)
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the progression of ESCC. In Han patients, we observed 
that the PFN2 protein expression progressively increased 
from NEE to LGIN, to ESCC, peaking in HGIN, which 
indicated that PFN2 would soon increase once the 
esophageal squamous epithelium transformed into ESCC 
malignant progression. Patients with mild, moderate 
and severe dysplasia as well as in  situ carcinoma have 
an increased risk of developing aggressive ESCC [40]. 
Similarly, the PFN2 protein expression was significantly 
higher in Kazakh ESCC than in NEE. Although the two 
groups had different ethnic customs and dietary histories, 
high level of PFN2 protein was equally observed in both 
Han and Kazakh ESCC tissues. Therefore, we confirmed 
the notion that PFN2 might function as an oncogene 
of ESCC. As far as we concerned, this is the first report 
that exhibits high level of PFN2 protein inamongst ESCC 
patients from Chinese Han and Kazakh populations. A 
similar phenomenon was observed in ESIN tissues.
To investigate the feasibility of using PFN2 as a clinical 
diagnostic biomarker of ESCC and ESIN, we constructed 
ROC curves to assess the specificity and sensitivity of 
PFN2 in different types of tissues. We acquired high sen-
sitivity and specificity values that underscored the poten-
tial availability of PFN2 as a novel diagnostic biomarker. 
Notably, our initial data were only derived from immuno-
histochemical results, which constituted a sensitive and 
cost-efficient method for estimating protein expression 
[41]. This method has also been used to recognize sev-
eral potential diagnostic markers and therapeutic targets 
[42]. Therefore, other protein analytical methods should 
be used to further confirm the immunohistochemistry-
based results that are presented in this paper. In addition, 
we found that PFN2 expression influenced the survival of 
ESCC patients, with overexpression of PFN2 being asso-
ciated with worse OS. Cox regression analysis revealed 
that the PFN2 expression could serve as an independent 
prognostic factor for ESCC. The relations between PFN2 
expression and worse OS have been previously analyzed 
in several tumors. Previous studies also proposed that 
abnormal PFN2 expression could predict poor progno-
sis [19, 33]. Our results support the theory that abnormal 
PFN2 expression may serve as a prognostic biomarker, 
Table 3 Relationship of PFN2 expression between Kazakh 
and Han ESCC tissues
* Pearson’s χ2 test for comparison between groups





No. % No. %
PFN2 0.282
Nondysregulated 33 17.2 22 13.1
Dysregulated 159 82.8 146 86.9
Table 4 Correlation between PFN2 expression and clinicopathologic features in ESCC from Han and Kazakh population
* P < 0.05, as determined by Pearson’s χ2 test
Variables PFN2 expression in Han ethnic PFN2 expression in Kazakh ethnic
Total cases Low n (%) High n (%) P value Total cases Low n (%) High n (%) P value
Gender 0.817 0.173
 Male 137 23 (16.8) 114 (83.2) 108 17 (15.7) 91 (84.3)
 Female 55 10 (18.2) 45 (81.8) 60 5 (8.3) 55 (91.7)
Age (years) 0.658 0.916
 <59 98 18 (18.4) 80 (81.6) 101 13 (12.9) 88 (87.1)
 ≥59 94 15 (16.0) 79 (84.0) 67 9 (13.4) 58 (86.6)
Differentiation 0.162 0.305
 Well 67 15 (22.4) 52 (77.6) 39 7 (17.9) 32 (82.1)
 Moderate + poor 125 18 (14.4) 107 (85.6) 129 15 (11.6) 114 (88.4)
Invasion depth 0.004* 0.393
 T1–T2 79 21 (26.6) 58 (73.4) 83 9 (10.8) 74 (89.2)
 T3–T4 113 12 (10.6) 101 (89.4) 85 13 (15.3) 72 (84.7)
Lymph node metastasis 0.945 0.010*
 No 127 22 (17.3) 105 (82.7) 79 16 (20.3) 63 (79.7)
 Yes 65 11 (16.9) 54 (83.1) 89 6 (6.7) 83 (93.3)
TNM stage 0.822 0.796
 I + II 154 26 (16.9) 128 (83.1) 111 14 (12.6) 97 (87.4)
 III + IV 38 7 (18.4) 31 (81.6) 57 8 (14.0) 49 (86.0)
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which in turn highlights the implication that an increased 
PFN2 expression can be an early indicator of high-risk 
population and prognostic biomarker.
Another important finding in this study was found that 
PFN2 expression was positively associated with inva-
sion depth amongst Han patients with ESCC, as well as 
lymph node metastasis amongst Kazakh ESCC patients. 
Therefore, PFN2 overexpression may be important for 
the development of ESCC and can promote the metas-
tasis and aggressiveness of ESCC. Nevertheless, the 
inconsistent conclusions from these two groups might 
be attributed to the restrictions in the sample size, the 
heterogeneity of the population and their different 
hereditary backgrounds. Therefore, these findings should 
be explored further in future studies by using uniform 
ethnic cohorts and employing a larger sample size. Our 
findings are compatible with those of several reports on 
PFN2 in other types of tumors. For instance, one research 
showed that PFN2 mRNA levels and protein were signifi-
cantly up-regulated in lung cancer tissues, whilst PFN2 
overexpression strongly promoted lung cancer migra-
tion and invasion [19]. Another study reported that up-
regulated PFN2 expression in colorectal cancer stem 
cells enhanced the ability of migration and invasion [34, 
43]. By contrast, Ma et  al. observed a decreased PFN2 
protein expression in OSCC tissues and suggested that 
Fig. 3 Kaplan–Meier survival curves for patients with high PFN2 expression and those with low expression. a ESCC patients with high PFN2 expres‑
sion (IS ≥ 4) experienced a significantly shorter survival period after surgery than those with low PFN2 expression (IS < 4) (P < 0.05). b Patients with 
high PFN2 expression had a greater risk of death than those with low PFN2 expression (P < 0.05)
Table 5 Univariate and multivariate Cox regression analyses of the prognostic variables in ESCC patients
HR hazard ratio, CI confidence interval, * P < 0.05
Variables Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
PFN2 expression (IS ≥ 4) 2.669 1.147 6.209 0.023* 2.465 1.020 5.955 0.045*
Gender (female) 1.734 0.910 3.303 0.094 1.574 0.780 3.176 0.206
Age (≥59 years) 0.882 0.483 1.870 0.950 1.027 0.481 2.191 0.945
Differentiation (well) 0.739 0.339 0.394 1.385 0.610 0.316 1.177 0.140
Invasion depth (T2–T3) 3.085 1.079 8.819 0.036* 1.087 0.271 4.368 0.906
Lymph node metastasis (yes) 1.147 0.590 2.228 0.686 1.198 0.595 2.415 0.613
TNM Stage (III + IV) 2.981 1.380 6.437 0.005* 3.037 1.094 8.833 0.033*
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the down-expression of PFN2 in OSCC tissues was sig-
nificantly associated with vascular invasion and advanced 
TNM stage [33]. These contradictory results might be 
attributed to the heterogeneity of the tumor and the lim-
ited sample size. Moreover, PFN2 molecules could bind 
tightly with a proline-rich motif, and various proteins 
contain one or more proline-rich motifs, such as Ena/
VASP proteins (Mena, VASP and EVL) [44–46], Arp2/3 
complex [47] and WASP [48]. Therefore, PFN2 may be 
involved in the regulation of different signaling pathways, 
such as PI3K–AKT [49] and TGF-β/Smad signaling [19], 
thereby leading to different biological consequences. 
Therefore, further research must elucidate the associa-
tion of PFN2 expression with the invasion and metastasis 
of ESCC by employing a larger sample.
In epithelial cancers, EMT is regarded as one of the 
major molecular mechanisms that promote invasion and 
metastasis [50, 51]. Loss of E-cadherin is a fundamental 
step of EMT by which polarized epithelial cells lose the 
tight cell–cell junction and enhance the migratory capac-
ity. In our study, E-cadherin was clearly up-regulated by 
the knockdown of PFN2. This result was in agreement 
with the decreased migration and invasion abilities of 
ESCC cells. Some reports showed that several EMT-
inducing transcription factors, such as Snail, Slug and 
ZEB1, could directly or indirectly repress E-cadherin to 
promote invasion and metastasis [52, 53]. Snail and Slug 
could bind to the E-box hexa-nucleotide DNA motif in 
the human E-cadherin promoter by a resembling struc-
ture with a highly conserved carboxy-terminal domain 
Fig. 4 ROC curve analysis of the PFN2 IHC scores for detecting precancerous lesions and ESCC tissues. a ESCC tissues, b HGIN tissues, and c LGIN tis‑
sues of the Chinese Han population and d ESCC tissues of the Kazakh population from the controls. The area under the curve (AUC) is 0.893, 0.947, 
0.743, and 0.860, respectively
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Fig. 5 Change in EMT phenotype and morphology after PFN2‑siRNA transfection in ESCC cells. a After silencing of PFN2 with PFN2‑siRNA in ESCC 
cells, the protein levels of E‑cadherin, Vimentin, Snail, Slug and ZEB1 were measured by Western blot. (Bar chart showing) Relative protein levels of 
E‑cadherin, Vimentin, Snail, Slug and ZEB1 normalized to β‑actin in b ECa109 cells, c EC9706 cells and d TE‑1 cells. e Morphological change images 
of ECa109 cells after transfecting with PFN2‑siRNA for 24, 36, and 48 h
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[54]. ZEB1 induces EMT by down-regulating E-cadherin 
and up-regulating a range of mesenchymal markers, such 
as N-cadherin, Vimentin and MMPs, thereby promoting 
cell migration, invasion and metastasis [55]. In our study, 
silencing PFN2 significantly suppressed the expressions 
of Snail, Slug and ZEB1. These results were consistent 
with those of previous lung cancer studies [19]. In lung 
cancer, PFN2 has been identified as a critical activator 
of TGF-β/Smad signal-inducing EMT. Similarly, another 
mesenchymal marker, Vimentin, was obviously down-
regulated by the knockdown of PFN2. Vimentin is a fila-
ment that is highly expressed in mesenchymal cells and 
is generally used to determine those tumor cells that are 
undergoing EMT based on the positive association of 
Vimentin expression with the invasion and metastasis in 
multiple cancers [56]. Notably, our results were accorded 
with previous ESCC studies [57]. Pang et al. were the first 
to report that the TGF-β1/Smad signaling pathway could 
induce EMT in ESCC. Unsurprisingly, the silencing of 
PFN2 significantly reversed the fibroblastoid-like pheno-
type of ESCC cells. In other words, the depletion of PFN2 
suppressed the invasion and metastasis of ESCC cell lines 
as well as induced the reversion of EMT, which suggested 
that PFN2 enhanced the invasion and metastasis of ESCC 
cell lines by inducing EMT. We contend that PFN2 may 
promote invasion and metastasis by activating the TGF-
β1/Smad signaling pathway inducing EMT in ESCC, but 
this contention must be clarified further.
However, it must be pointed out that, in the present 
study, we adopted an approach similar to that of Valen-
zuela–Iglesias et  al. [58]. Specifically, we detected the 
PFN2 expression as a whole and did not further distin-
guish the isoforms of PFN2. Therefore, the differences 
between PFN2a and PFN2b in terms of ESCC progres-
sion should be clarified in future studies.
Conclusions
In summary, our clinical study has characterized PFN2 as 
a molecular marker for ESCC progression and metastasis, 
and more importantly, our study has identified an inde-
pendent prognostic factor for ESCC patients, indicating 
that PFN2 could serve as an early detector of ESCC high-
risk population and a novel prognostic marker for ESCC. 
Moreover, we found knockdown of PFN2 significantly 
reduced migration and invasion by mediating EMT 
phenotype in vitro. Targeting PFN2 may offer a promis-
ing therapeutic strategy for ESCC treatment.
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